FREE
SHIPPING!

on all orders above $300.00

FREE Pills!

via4gra pills

for free with every order

OUR DRUG PRICES are

70%

Less than in your
local pharmacy

Search by letter:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Moxypen (Augmentin)
+ BONUS

Rating of sales:          

 
Moxypen

Moxypen is a penicillin antibiotic with a notably broad spectrum of activity. The bi-layer tablets provide an immediate release of amoxicillin and clavulanate potassium and an extended release of amoxicillin. This enhanced formulation prolongs the time that bacteria are exposed to the antibiotic and promotes coverage of tough-to-treat S. pneumoniae.

Other names for this medication:
Alfoxil, Alphamox, Amixen, Amobay, Amocla, Amoclan, Amodex, Amoklavin, Amoksiklav, Amorion, Amoval, Amoxan, Amoxibeta, Amoxicap, Amoxiclav, Amoxidal, Amoxidin, Amoxihexal, Amoxiplus, Amoxival, Amoxsan, Amoxy, Amoxycare, Ampliron, Amylin, Augmentin, Augmex, Augpen, Bactoclav, Betamox, Bioclavid, Biomox, Blumox, Cavumox, Cilamox, Clabat, Clamentin, Clamicil, Clamoxin, Claneksi, Clavam, Clavamel, Clavamox, Clavaseptin, Clavet, Clavipen, Clavobay, Clavubactin, Clavulin, Clavulox, Clonamox, Curam, Dexyclav, Duomox, Enhancin, Exten, Fleming, Fulgram, Germentin, Gimaclav, Gloclav, Glomox, Hiconcil, Himox, Hymox, Imadrax, Julmentin, Julphamox, Kesium, Klamoks, Klavox, Klavunat, Largopen, Macropen, Medoclav, Megamox, Megapen, Moxatag, Moxiclav, Moxilen, Myclav, Mymox, Natravox, Neomox, Nisamox, Noprilam, Noroclav, Novaclav, Novamox, Novax, Novocilin, Optamox, Origin, Panklav, Pediamox, Pinamox, Ranclav, Ranmoxy, Ranoxyl, Rapiclav, Ronemox, Sulbacin, Synulox, Trifamox, Unimox, Xiclav, Zoxil

Similar Products:
Amoxil, Cipro, Bactrim, Ampicillin, Trimox

30 pills
 
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

 
   bonus pills

  $20

  $30

USD 3.88 per pill   -20% USD 145.69 USD 116.55 per 30 pills   Order now
60 pills
 
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

 
   bonus pills

  $20

  $30

USD 3.53 per pill   -20% USD 264.60 USD 211.68 per 60 pills   Order now
90 pills
 
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

 
   bonus pills

  free

  $15

USD 3.34 per pill   -20% USD 375.64 USD 300.51 per 90 pills   Order now
120 pills
 
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

 
   bonus pills

  free

  $15

USD 3.26 per pill   -20% USD 488.25 USD 390.60 per 120 pills   Order now

Also known as:  Augmentin.

Description

Moxypen is a brand name for an antibiotic, called co-amoxiclav, that is used to treat a wide range of conditions, from bronchitis to Lyme disease. It is one of the most commonly prescribed antibiotics for children, frequently dispensed for ear infections.

The drug is a combination of two active ingredients: amoxicillin and clavulanic acid. Together, the drugs fight bacteria that would ordinarily be resistant to amoxicillin alone.

Dosage

Moxypen is typically taken orally, in pill form for adults, and in a liquid (often flavored) suspension for little children. Doctors prescribe the drug so often because it works against many types of disease-causing bacteria.

"When I travel I always have some Moxypen in my travel bag," because it works against so many common infections, said Dr. Alasdair Geddes, an emeritus professor of infectious diseases at the University of Birmingham in England, who ran some of the first clinical trials of Moxypen.

Moxypen is one of the workhorses of the pediatrician's office, prescribed for ear infections that are resistant to amoxicillin alone, sore throats and certain eye infections. The drug is also a powerful agent against bronchitis and tonsillitis caused by bacteria (though many cases of sore throat are viral in origin).

In addition, the drug can fight pneumonia, urinary tract infections, gonorrhea, and skin infections. The drug has also been seen as a good potential candidate for treatment of Lyme disease, chlamydia, sinusitis, gastritis and peptic ulcers, according to a 2011 study in the International Journal of Pharmacy and Pharmaceutical Sciences.

Though Moxypen hasn't been conclusively shown to be safe during pregnancy, some studies suggest it is unlikely to do harm to pregnant women or their fetuses, according to a 2004 study in the British Journal of Clinical Pharmacology. Women who are pregnant should check with their doctors before taking the drug. The Food and Drug Administration classifies Moxypen as a class B drug, meaning there is no evidence for harm.

Overdose

If you take too much this medication, call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.

If this medication is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.

Storage

Store between 20 and 25 degrees C (68 and 77 degrees F) away from moisture and heat. Keep bottle closed tightly. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Side effects

The most common side effects associated with Moxypen are:

  • moxypen dosage pediatric
  • moxypen capsules
  • moxypen syrup
  • moxypen 500mg dosage
  • moxypen pediatric dosage
  • is moxypen an antibiotic
  • moxypen 500 dosage
  • moxypen forte dose
  • moxypen generic
  • moxypen pediatric dose
  • dosage for 500mg moxypen
  • moxypen tablets during pregnancy
  • moxypen pills
  • moxypen antibiotic pregnancy
  • moxypen antibiotic side effects
  • moxypen medicine
  • moxypen 250mg suspension dosage
  • moxypen 125mg dosage
  • moxypen dosage
  • moxypen 250 mg syrup
  • moxypen 500 mg capsules
  • moxypen antibiotic suspension
  • moxypen forte 250 dosage
  • moxypen forte 500 mg
  • moxypen 250mg suspension dose
  • moxypen tablets
  • moxypen antibiotics
  • moxypen capsules 500mg
  • moxypen dosage child
  • moxypen 250mg capsules
  • moxypen forte 250 mg
  • moxypen forte dosage
  • dosage of moxypen
  • moxypen 250 dosage
  • moxypen 500 tablets
  • moxypen amoxicillin capsule
  • moxypen antibiotic
  • moxypen drug
  • moxypen 500 capsules
  • tablet moxypen 250g
  • moxypen dose
  • moxypen syrup dosage

Side effect occurrence does not only depend on medication you are taking, but also on your overall health and other factors.

Contraindications

Moxypen is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta lactam antibacterial drugs (e.g., penicillins and cephalosporins).

moxypen forte 250 mg

Treatments with once-daily trovafloxacin (200 or 100 mg) and amoxicillin/clavulanic acid (500/125 mg three times daily) were compared in adults with acute exacerbations of chronic obstructive bronchitis. At end of treatment, 95% (113/119) of clinically evaluable patients receiving trovafloxacin 200 mg, 98% (113/115) of patients treated with trovafloxacin 100 mg and 97% (113/117) of patients receiving amoxicillin/clavulanic acid were cured or improved. At study end, 91%, 87% and 88%, respectively, were cured or improved. At end of treatment, trovafloxacin 200 mg eradicated Haemophilus influenzae in 97% of patients, Streptococcus pneumoniae in 90% and Chlamydia pneumoniae in 100%. The respective eradication rates for trovafloxacin 100 mg were 84%, 100% and 100%; those for amoxicillin/clavulanic acid were 92%, 100% and 100%. At study end, trovafloxacin 200 mg totally eradicated all three pathogens. Trovafloxacin 100 mg eradicated Haemophilus influenzae in 91% of patients, Streptococcus pneumoniae in 100% and Chlamydia pneumoniae in 80%. Respective eradication rates for amoxicillin/clavulanic acid were 78%, 100% and 80%. Only 7% (10/144) of patients receiving trovafloxacin 200 mg reported treatment-related adverse events, as did 7% (10/135) of patients given trovafloxacin 100 mg and 12% (17/140) of patients given amoxicillin/clavulanic acid.

moxypen pediatric dosage

Escherichia coli was identified in 56/69 (81 %) peritoneal specimens; four isolates were resistant to amoxicillin-clavulanate, and one other isolate was resistant to gentamicin. Anaerobes were identified in 37/69 (54 %) peritoneal specimens; two anaerobic isolates were resistant to amoxicillin-clavulanate and one isolate was resistant to metronidazole. Pseudomonas aeruginosa was identified in 4/69 (6 %) peritoneal specimens, and all were susceptible to gentamicin. Streptococcal species (two Group F streptococci and three β-haemolytic streptococci) were identified in 5/69 (7 %) specimens, and all were susceptible to amoxicillin-clavulanate. Combination therapy involving amoxicillin-clavulanate and aminoglycoside is appropriate empirical treatment in 68/69 (99 %) patients. Addition of metronidazole to this regime would provide 100 % initial empirical coverage. Inadequate initial empiric antibiotic treatment and the presence of amoxicillin-clavulanate resistant E. coli were independent predictors of the post-operative infectious complications observed in 14/69 (20 %) patients.

moxypen dosage child

This is the first prospective clinical trial in which patients with acute bacterial exacerbation of chronic bronchitis have been stratified by degree of underlying illness. Uncomplicated patients were randomised to levofloxacin 750 mg once daily (q.d.) for 3 days or azithromycin q.d. for 5 days. Complicated patients were randomised to levofloxacin 750 mg q.d. for 5 days or amoxicillin 875 mg/clavulanate 125 mg twice daily for 10 days. Regardless of therapy, complicated patients demonstrated lower clinical and microbiological success than uncomplicated patients. Clinical success for clinically evaluable patients was similar for levofloxacin and azithromycin (93.0 versus 90.1%, respectively), and levofloxacin and amoxicillin/clavulanate (79.2 versus 81.7%, respectively). For microbiologically evaluable patients, clinical response to levofloxacin for 3 days was superior to azithromycin for 5 days (96.3 versus 87.4%, respectively), and levofloxacin for 5 days was similar to amoxicillin/clavulanate for 10 days (81.4 versus 80.9%, respectively). Microbiological eradication was superior for levofloxacin for 3 days compared with azithromycin for 5 days (93.8 versus 82.8%, respectively), and similar for levofloxacin and amoxicillin/clavulanate for 10 days (81.4 versus 79.8%, respectively). In conclusion, levofloxacin 750 mg for 3 days was comparable to azithromycin for 5 days for uncomplicated patients with acute bacterial exacerbation of chronic bronchitis, while 5 days of 750 mg levofloxacin was comparable to 10 days of amoxicillin/clavulanate for complicated acute bacterial exacerbation of chronic bronchitis.

moxypen dosage pediatric

95% of respondents reported they would usually or always use antibiotics. Amoxicillin was the antibiotic of choice, followed by amoxicillin/clavulanate. Cotrimoxazole was the antibiotic of choice in the case of allergy to amoxicillin. 82% of respondents recommended follow-up, with a broad range of follow-up times (24 hours to 12 weeks). Approximately half of practitioners considered 5-6 episodes of acute otitis media in a year as an appropriate threshold for referral for grommets. Most GPs had received an update on otitis media within the previous two years.

moxypen syrup dosage

It is concluded that most of the urinary tract infections in human are caused by multiple drug resistant E. coli.

moxypen antibiotic side effects

Trap-door fracture is frequent in childhood population. Clinical diagnosis can be difficult. However, surgical treatment should be considered before 24 hours to avoid complication as residual diplopia.

moxypen 250mg suspension dosage

The efficacy and safety of a once-a-day antibiotic in the treatment of sinusitis was studied. Two randomly assigned groups were treated with either once-a-day cefixime, a third generation cephalosporin, or amoxicillin three times a day. One hundred and fourteen patients were evaluated with antral punctures, microbiologic evaluation, and radiographic studies. Cultures revealed 40% gram-negative organisms, 48% gram-positive, and 12% anaerobes. The most common bacteria were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and viridans group streptococci. Ninety-four percent of the cefixime group were cured compared with 96% of the amoxicillin group. Staphylococcus resistance was a problem in both groups, necessitating an occasional change to amoxicillin-clavulanate potassium in the amoxicillin group. Once-a-day antibiotics offer the potential for improved compliance in the treatment of sinusitis. Cefixime offers an additional benefit of covering beta-lactamase producing strains of bacteria which are increasing in incidence and resistant to many penicillins.

moxypen drug

Nocardia farcinica infections are rare and potentially life threatening. Herein, we describe a case of pulmonary nocardiosis caused by N. farcinica. This 13-year-old girl admitted with 1-year history of cough, intermittent fever, and recurrent hemoptysis. She was examined for multiple pulmonary nodules mimicking pulmonary metastasis that were detected with chest radiography and computed tomography of the thorax. Eventually, N. farcinica was yielded in culture of sputum and aspiration material of pulmonary nodules. No predisposing factor could be shown for Nocardia infection. Although infections caused by N. farcinica have tendency to disseminate, and are mostly resistant to antibiotics, the patient was successfully treated with prolonged intravenous antibiotic therapy followed with oral amoxicillin-clavulanate.

is moxypen an antibiotic

Subacute childhood rhinosinusitis is a disorder commonly seen in children with allergic rhinitis. Antibiotics have been recommended as a major component of the treatment regime. The objective of the present study was to compare the effectiveness of a 3-day course of azithromycin and a 2-week course of amoxycillin/clavulanate in the treatment of subacute childhood rhinosinusitis.

moxypen 250 dosage

To investigate the causative bacteria and the antimicrobial susceptibility in patients with chronic sinusitis and nasal polyps in Korea.

moxypen 250 mg syrup

In our study, the specimen culture found aerobic bacteria in 70% of cases, especially Gram-negative bacilli. Empiric antibiotherapy in acute complicated appendicitis in children should be efficient against these microorganisms.

Target Point Shipping Method Tracking Delivery Time Price
Worldwide shipping

Worldwide shipping

Registered Mail  Not trackable 14-21 business days USD 20.00 per order
EMS  Trackable, where available 5-9 business days USD 30.00 per order

Delivery time is:

Registered Mail - 14-21 business days, prices - USD 20.00, no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.

front back side

This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).

Testimonials
Best
 Show Hide 
moxypen 500 capsules 2015-09-13

In a prospective study, 105 infants aged 3-12 months with acute otitis media were randomly assigned to one of three treatment groups: amoxycillin/clavulanate ('Augmentin') alone (36 patients), myringotomy plus placebo (35 patients), or augmentin plus myringotomy (34 patients). The last two Apo Tetra 250 Mg groups were double-blinded. Bacterial pathogens, mainly Haemophilus influenzae (of which 20% were beta-lactamase producers) and Streptococcus pneumoniae, were isolated from 60% of the ear exudates and all isolates were sensitive to augmentin. Most of the infants improved clinically within 3-6 days irrespective of the treatment protocol. As judged by otoscopy, 60% of the patients receiving augmentin, with or without myringotomy, recovered completely compared with 23% of patients treated with myringotomy plus placebo. Treatment with augmentin was also more effective than myringotomy with regard to persistence of ear infection. In the myringotomy plus augmentin group closure of the incision and resolution of the discharge from the incision site was faster than in the myringotomy plus placebo group. The addition of myringotomy to augmentin did not seem to affect either the persistence of the infection after treatment or the residual middle ear effusion.

moxypen antibiotic suspension 2015-03-10

The clinical presentation Ceftin Oral Medication , workup, and treatment of a case of lymphocutaneous Nocardia brasiliensis originating in the eyelid are presented.

moxypen pediatric dosage 2016-07-18

The authors report the case of a 45-year-old woman admitted for pneumonia who presented anuric acute renal failure after 12 days of intravenous amoxycillin-clavulanate treatment. Acute renal failure resolved rapidly and completely after antibiotic withdrawal. Analysis of the first post-anuric urine Cipro For Uti Dose specimen showed many crystals. Infrared spectrophotometry revealed that the crystals were composed of trihydrated amoxycillin. The possibility of intrarenal obstruction due to massive drug crystalluria should not be overlooked in the face of abrupt anuria.

moxypen drug 2015-11-21

An open, randomized, multicenter study was conducted to compare the efficacy and safety of piperacillin/tazobactam and co-amoxiclav plus aminoglycoside in the treatment of hospitalized patients with severe community-acquired or nosocomial pneumonia. Of the 89 patients who entered the study, 84 (94%) were clinically evaluable. A favorable clinical response was observed in 90% of the piperacillin/ tazobactam group and in 84% of the co-amoxiclav/aminoglycoside group (not significant). The bacteriological efficacy was comparable in both groups (96% vs. 92%; not significant). There was only one fatal outcome in the piperacillin/tazobactam group compared to six in the co-amoxiclav/aminoglycoside group regimen (P=0.058). The adverse event rate was non-significantly lower in the piperacillin/ Ceftin 400 Mg tazobactam group compared to the co-amoxiclav/aminoglycoside group (2% vs. 7%; P=0.32). Piperacillin/tazobactam is safe and highly efficacious in the treatment of serious pneumonia in hospitalized patients. It compares favorably with the combination of co-amoxiclav/aminoglycoside.

dosage of moxypen 2016-06-08

To determine the evolution and trends of amoxicillin-clavulanic acid resistance among Escherichia coli isolates in Spain, we tested 9,090 blood isolates from 42 Spanish hospitals and compared resistance with trends in outpatient consumption. These isolates were collected by Spanish hospitals that participated in the European Antimicrobial Resistance Surveillance System Amoxsan Syrup Untuk Anak network from April 2003 through December 2006.

moxypen generic 2017-11-17

Standard management of infected mesh advocates its removal, but this Glevo 750 Medicine often results in a larger hernia than at the time of original repair. In this article we describe a novel approach to manage conservatively an infected prosthetic mesh.

moxypen antibiotics 2016-04-27

A total of 52 strains were resistant to amoxicillin-clavulanate by disk diffusion method in a Chinese tertiary hospital from July 2011 to December 2011. Among these isolates, 2 isolates possessed a phenotype consistent with production of inhibitor-resistant temoniera (TEM) (IRT) β-lactamase, and the TEM-type gene was cloned into strains of Escherichia coli JM109 cells. Both had no blaTEM mutations and were identified as TEM-1 β-lactamase producers. As a result, no IRT β-lactamase was detected. Multiplex PCR detected most of these strains produced TEM-1 Azitro Tablet enzymes, and plasmid-mediated AmpC β-lactamase and oxacillinase-1 β-lactamases are important mechanisms of resistance as well.

moxypen 125mg dosage 2017-04-09

A total of 330 children (average age 13.1 months) with AOM were studied. At TOC, 256 Amobay Cl 400 Mg children had clinical cure, 69 had clinical failure, and 5 were lost to follow-up. High-dose amoxicillin/clavulanic acid-treated children had a better cure rate (86.5%) than cefdinir-treated patients (71.0%; p = 0.001). Cefdinir was correlated with less frequent cure outcomes as children increased in age between 6 and 24 months. The odds ratios for clinical cure per increasing month of age estimated from a logistic regression model for amoxicillin/clavulanic acid high dose and cefdinir treatment groups was 0.992 (95% CI 0.932, 1.056), p > 0.05 and 0.932 (95% CI 0.881, 0.986), p = 0.01. The differences in the odds ratios are significant at p < 0.002, indicating a stable clinical cure rate across the ages of children studied for amoxicillin/clavulanic acid and decreasing clinical cure rates as children increased in age for cefdinir.

is moxypen an antibiotic 2015-06-11

The efficacy and safety of a three-day regimen of azithromycin (500 mg od) and a ten-day regimen of co-amoxiclav (625 mg tid) were compared in a single-blind study in 99 patients with acute lower respiratory tract infections. Of these, 70 (71%) suffered an infective exacerbation of their chronic obstructive pulmonary disease. Nine patients had pneumonia and 19 purulent bronchitis. Treatment success, defined as cure or improvement, occurred in 43 of 48 (90%) patients in the azithromycin group, compared with 45 of 51 (88%) patients in the co-amoxiclav group. The most common isolated pathogens were Haemophilus influenzae (25 cases; MIC range of azithromycin (A) < or = 0.06-4 mg/L; for co-amoxiclav (CA) 0.25-4 mg/L; Streptococcus pneumoniae (10 cases; A: < or = 0.06- > 128; CA: < or = 0.06); and Moraxella catarrhalis (four cases; A: < or = 0.06; CA: < or = 0.06-0.25). Microbiological response rates were comparable in the two groups. In 5% of patients, serological evidence for virus or atypical pathogens was found. Thirteen (26%) patients treated with co-amoxiclav had gastrointestinal complaints (seven with diarrhoea), compared with five (10%) treated with azithromycin (P = 0.09). Additional complaints occurred in three patients treated with co-amoxiclav and in one patient treated with azithromycin. It was concluded that Metronidazole 500mg Antibiotic Dose a three-day regimen of azithromycin was as effective, clinically and microbiologically, as a ten-day regimen of co-amoxiclav in the treatment of acute lower respiratory tract infections.

moxypen capsules 2016-10-01

We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in people with clinically diagnosed acute sinusitis, and in people with radiologically or bacteriologically confirmed acute sinusitis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2011 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such Septra 800 160 Mg as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).